Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB1 | P05556 | 6/20 | 0.50 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.50 |
| ▸ | ITGB3 | P05106 | 5/20 | 0.44 |
| ▸ | ITGAV | P06756 | 5/20 | 0.44 |
| ▸ | ITGA5 | P08648 | 5/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 5/20 | 0.43 |
| ▸ | MAPT | P10636 | 5/20 | 0.43 |
| ▸ | POLB | P06746 | 2/20 | 0.43 |
| ▸ | ITGA2B | P08514 | 3/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.42 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | LY96 | Q9Y6Y9 | 1/20 | 0.40 |
| ▸ | ITGB5 | P18084 | 1/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | MLYCD | O95822 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8230444 | 1.00 | ITGB1 (0.50) | ITGB1ITGA4ITGB3ITGAVITGA5 | |
| SCHEMBL4181347 | 0.86 | ITGB1 (0.50) | ITGB1ITGA4ITGB3ITGAVITGA5 | |
| SCHEMBL8232087 | 0.86 | ITGB1 (0.50) | ITGB1ITGA4ITGB3ITGAVITGA5 | |
| SCHEMBL4188079 | 0.84 | ITGB1 (0.64) | ITGB1ITGA4ITGB3ITGAVITGA5 | |
| SCHEMBL27741499 | 0.82 | MAPT (0.41) | TDP1MAPTPOLBNPSR1NTSR1 | |
| SCHEMBL8232058 | 0.78 | NLRP3 (0.59) | ITGB1ITGA4ITGB3ITGAVITGA5 | |
| SCHEMBL4194979 | 0.78 | NLRP3 (0.59) | ITGB1ITGA4ITGB3ITGAVITGA5 | |
| SCHEMBL13762119 | 0.77 | L3MBTL1 (0.58) | ITGB1ITGA4ITGB3ITGAVITGA5 | |
| SCHEMBL2359788 | 0.77 | CTSS (0.50) | ITGB3MAPTITGA2B | |
| SCHEMBL13755099 | 0.76 | ITGB1 (0.50) | ITGB1ITGA4ITGB3ITGAVITGA5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8309735-B2 | Heterocyclic compounds for the inhibition of integrins and use thereof | SHIRE ORPHAN THERAPIES GMBH (DE) | 2012-11-13 | — | — | US | disclosed |
| US-20090203745-A1 | HETEROCYCLIC COMPOUNDS FOR THE INHIBITION OF INTEGRINS AND USE THEREOF | JERINI AG (DE) | 2009-08-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090203745-A1 | HETEROCYCLIC COMPOUNDS FOR THE INHIBITION OF INTEGRINS AND USE THEREOF | ITGB1, ITGA2, ITGB2 | ITGB1 1/4885ITGA4 13/4885ITGB3 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.